SCHEMBL6728752

SCHEMBL6728752

Cc1cc(C)cc(-c2noc(CO)c2-c2ccc(S(N)(=O)=O)c(F)c2)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.50
PTGS1 P23219 4/20 0.43
BRD4 O60885 2/20 0.39
BRD2 P25440 1/20 0.38
BRD3 Q15059 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
CA7 P43166 3/20 0.38
CA4 P22748 2/20 0.37
PDE3A Q14432 1/20 0.37
ALDH1A1 P00352 1/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6729399 0.92 PTGS2 (0.54) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6718472 0.91 PTGS2 (0.53) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6723184 0.90 PTGS2 (0.51) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6721675 0.90 PTGS2 (0.43) PTGS2PTGS1BRD4PDE3AALDH1A1
SCHEMBL6723385 0.90 PTGS2 (0.47) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6723064 0.89 PTGS2 (0.50) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6721401 0.89 PTGS2 (0.52) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6719265 0.88 PTGS2 (0.49) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6719228 0.88 PTGS2 (0.49) PTGS2PTGS1BRD4BRD2BRD3
SCHEMBL6723263 0.88 PTGS2 (0.51) PTGS2PTGS1BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-05-13 US disclosed
EP-1296971-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2003-04-02 EP disclosed
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2002-12-05 US disclosed
WO-2001081332-A2 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183362-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, FPR1, PTGES2 PTGS2 5/4885PTGS1 4/4885BRD4 384/4885
US-20040092552-A1 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation FPR2, PTGES2, FPR1 PTGS2 5/4885PTGS1 4/4885BRD4 340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.